Trailing-twelve-month (TTM) revenue is $2.78 Billion with a year-over-year growth of +24.67%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $659,903,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-23 |
| Q4 FY2025Period ended 2025-12-31 | $708,450,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-10 |
| Q1 FY2026Period ended 2026-03-31 | $706,604,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-23 |
| Q2 FY2026Period ended 2026-06-30 | $707,331,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-23 |
| TTM revenue | $2,782,288,000 |
Current P/S: $17,205,888,348 market capitalization ÷ $2,782,288,000 TTM revenue = 6.18x.
Market capitalization source: FMP quote. Quote observed 2026-09-16T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $707.33M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-17T08:55:43.683Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Antiviral And Anti Infective | N/A | $111M | $118M | $163M | $156M | $135M |
| Cardiology | N/A | $120M | $175M |
$2.78B
$2.78 Billion
+24.67%
vs. $2.23B a year ago (TTM)
+22.03%
5 Year compound annual growth rate
1 Year
+24.67%
3 Year
+18.48%
5 Year
+22.03%
10 Year
+21.60%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.53B | +$421.18M | +19.97% |
| 2024 | $2.11B | +$223.21M | +11.84% |
| 2023 | $1.89B | +$425.85M | +29.17% |
| 2022 | $1.46B | +$317.62M | +27.80% |
| 2021 | $1.14B | +$216.45M | +23.38% |
| 2020 |
TTM Growth
+24.67%
3-Year CAGR
+18.48%
5-Year CAGR
+22.03%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-17T08:55:43.683Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $194M |
| $230M |
| $239M |
| Central Nervous System | N/A | $122M | $158M | $160M | $182M | $255M |
|---|
| Metabolic | N/A | $160M | $245M | $377M | $458M | $745M |
|---|
| Oncology | N/A | $363M | $468M | $587M | $651M | $748M |
|---|
| Other | N/A | $267M | $297M | $405M | $431M | $409M |
|---|
| Revenue Net | $16M | $35M | $1.5B | $1.9B | N/A | N/A |
|---|
| $925.92M |
| +$64.96M |
| +7.54% |
| 2019 | $860.97M | +$156.38M | +22.19% |
| 2018 | $704.59M | +$268.44M | +61.55% |
| 2017 | $436.15M | +$14.57M | +3.46% |
| 2016 | $421.58M | +$62.52M | +17.41% |
